Hubei Cancer Hospital

Hubei 430079

0 studies enrolling now · 3 studies all time

What they study most

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation, Non-small Cell Lung Cancer, Platinum-resistant Ovarian Cancer

Studies at this site

• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian — Completed
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early